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Background: Krill contains two marine omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), mainly bound in phospholipids. Typical products from krill are krill oil and krill meal.
Fish oils contain EPA and DHA predominantly bound in triglycerides. The difference in the chemical binding of
EPA and DHA has been suggested to affect their bioavailability, but little is known on bioavailability of EPA and
DHA in krill meal.
This study was undertaken to compare the acute bioavailability of two krill products, krill oil and krill meal, with fish oil
in healthy subjects.
Methods: A randomized, single-dose, single-blind, cross-over, active-reference trial was conducted in 15 subjects, who
ingested krill oil, krill meal and fish oil, each containing approx. 1 700 mg EPA and DHA. Fatty acid compositions of
plasma triglycerides and phospholipids were measured repeatedly for 72 hours. The primary efficacy analysis was based
on the 72 hour incremental area under the curve (iAUC) of EPA and DHA in plasma phospholipid fatty acids.
Results: A larger iAUC for EPA and DHA in plasma phospholipid fatty acids was detected after krill oil (mean 89.08 ±
33.36% × h) than after krill meal (mean 44.97 ± 18.07% x h, p < 0.001) or after fish oil (mean 59.15 ± 22.22% × h,
p=0.003). Mean iAUC’s after krill meal and after fish oil were not different. A large inter-individual variability in response
was observed.
Conclusion: EPA and DHA in krill oil had a higher 72-hour bioavailability than in krill meal or fish oil. Our finding that
bioavailabilities of EPA and DHA in krill meal and fish oil were not different argues against the interpretation that
phospholipids are better absorbed than triglycerides. Longer-term studies using a parameter reflecting tissue fatty acid
composition, like erythrocyte EPA plus DHA are needed.
Trial registration: NCT02089165
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In Western countries, like Germany or the United States,
mean levels of the marine omega-3 fatty acids eico-
sapentaenoic acid (EPA) and docosahexaenoic acid are
below the range defined as optimal [1]. In large parts, this
is due to a decline in uptake of EPA and DHA [1], but also
due to the fact that, under Western dietary conditions,
only a very low percentage (if any) of alpha-linolenic acid* Correspondence: Anton.Koehler@med.uni-muenchen.de
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unless otherwise stated.can be converted to EPA, and almost no conversion to
DHA occurs [2,3]. Therefore, sources of EPA and DHA
have to be ingested directly. Since the production of fish
oil cannot be increased easily, other sources of EPA and
DHA are currently investigated.
One of them is krill, a shrimp-like crustacean that feeds
off algae in deep ocean waters. Krill is rich in both EPA
and DHA. In Krill, 30–65% of EPA and DHA are in
phospholipid fatty acids, while in fish or fish oil, EPA and
DHA are mainly in triglycerides (sn-2 position) [4,5]. In
contrast to triglycerides, phospholipids are amphiphilic
and thus have emulsifying features, which might contributeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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detail elsewhere, bioavailability of EPA and DHA de-
pends on a host of factors, like composition of food
ingested with EPA and DHA (if any), other matrix ef-
fects, and others [5,6].
Thus, the bioavailability of any new source of EPA and
DHA has to be investigated in humans. Indeed, some re-
ports have demonstrated that EPA and DHA in krill oil
are bioavailable, and some indicating superior bioavail-
ability of EPA and DHA in krill oil, as compared to EPA
and DHA in fish oil [4,5,7]. However, to the best of our
knowledge (medline search on Dec 17, 2014), bioavail-
ability of EPA and DHA in krill meal remained to be in-
vestigated in humans.
Therefore, we compared the acute bioavailability of EPA
and DHA in two different krill products, krill meal
(Rimfrost Genuine, 40% oil content) and krill oil (Rimfrost
Sublime), to the bioavailability of EPA and DHA in fish oil.
In a randomized, cross-over trial, we provided a single dose
of about 1,700 mg EPA and DHA to human volunteers.
Subjects and methods
Study subjects
Study participants were recruited through an advertise-
ment in the local newspaper from the area of the Northern
Savo (Kuopio, Finland). Inclusion criteria were: (1) healthy
female and male subjects, (2) age between 18 and 65 years,
(3) body mass index (BMI) between 18.5 and 30 kg/m2.
Exclusion criteria were: (1) use of any medication with a
potential to affect the bioavailability of fatty acids (e.g.
lipid-lowering medication); (2) familial hypercholesterol-
emia, marked combined hyperlipidemia and any other
condition that might impair fat absorption (e.g. chronic
pancreatitis, pancreatic lipase deficiency syndrome); (3)
type 1 or type 2 diabetes; (4) cancer or any other malignant
disease within the past five years; (5) use of cyclic or any
other discontinuous hormone replacement therapy; (6) ≥
once a week of fatty fish (e.g. salmon, herring, sardines,
mackerel, vendace, anchovy) consumption; (7) regular
consumption of omega-3 supplements within 4 weeks
prior the randomization; (8) smoking; (9) alcohol con-
sumption of more than 15 units per week (1 unit=33 cl
beer/12 cl wine/4 cl sprits providing about 12 g alcohol);
(10) females who are pregnant, breast-feeding or intend to
become pregnant; (11) hypersensitivity to any of the com-
ponents of the test product (including fish allergy); and
(12) other medical reasons judged by the investigator to
render the subject unsuitable for the study participation.Table 1 Latin square design
Sequence 1 Krill oil supplement (A)
Sequence 2 Fish oil supplement (B)
Sequence 3 Krill meal (C)The trial was approved by the Research Ethics Committee
of the Hospital District of Northern Savo (Kuopio, Finland),
registered on Clinicaltrials.gov (NCT02089165), and con-
ducted according to the Declaration of Helsinki and Good
Clinical Practice. Written informed consent was obtained
from all subjects before any study related procedures.
Study design
A randomized, single-dose, single-blind, cross-over, active-
reference intervention trial was performed in healthy sub-
jects, comparing Antarctic Krill Oil, Antarctic Krill Meal,
and Fish Oil. The primary endpoint was the proportion of
EPA +DHA in plasma phospholipid fatty acids during
72 hour follow-up after ingestion, measured as incremen-
tal area under the curve (iAUCPL). Secondary endpoints
were the incremental area under the curve of EPA +DHA
in plasma triglyceride fatty acids (iAUCTG); maximum in-
creases of EPA, DHA and EPA +DHA from baseline and
time to maximum EPA, DHA and EPA +DHA in plasma
phospholipid fatty acids and triglyceride fatty acids, each
during 72 hours after ingestion.
Permuted block randomization was performed using the
incomplete 3 × 3 Latin square design (Table 1). Each sub-
ject was assigned to one of three sequences of interven-
tions in a non-concealed way (Table 1). Altogether 17
healthy subjects were randomized, and 15 subjects partici-
pated all three 72-hour tests periods as randomized. Each
participant received each treatment 13–29 days apart.
Blood samples were taken after a 10–12 hour overnight
fast 20 min before breakfast and at 2, 4, 6, 8, 12, 24–25,
48–50 and 72–74 hours after start of breakfast ingestion.
Subjects were served lunch, snack, dinner and supper im-
mediately after blood sampling at 4, 6, 8 and 12 hour after
start of breakfast ingestion, respectively. Subjects spent
the test days at the study center until supper was served,
and consumed. After supper, subjects went home and
returned to the study center the following three mornings
for blood sampling. The participants were not permitted
to consume any food or drink (except for one glass of
water in the morning before sampling) after supper until
the blood sample was taken at 24–25 hour after start of
the breakfast ingestion.
Standardized evening meal preceeding the test days
Participants were provided a standardized evening meal
the day before the test, consisting of 300 g commercial
ham and potato casserole (Saarioinen Oy, Kangasala,
Finland), tomato/cucumber and 300 ml of tap water. TheFish oil supplement (B) Krill meal (C)
Krill meal (C) Krill oil supplement (A)
Krill oil supplement (A) Fish oil supplement (B)
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pants were advised to warm up the casserole before eating
and measure the water dose. In addition, the participants
were permitted to consume optional amount of tomato
and or cucumber with the evening meal but were advised
to consume the same amount at each time. The partici-
pants were advised to eat the evening meal just before the
start of the overnight fast.
Standardized breakfast and products tested
The standardized breakfast meal included 2 open sand-
wiches (rye bread, fat spread, cheese, cucumber, tomato),
one boiled egg, 150 g of yoghurt and 400 ml of tap
water. The standardized breakfast (without the study
product) contained 2232 kJ, 43 g carbohydrates, 29 g fat
and 22 g protein. In addition, participants consumed one
of the following three: 1) 16 capsules of antarctic krill oil
(Rimfrost Sublime™, Olympic Seafood AS, Fosnavåg,
Norway), 2) 12.3 g of antarctic kill meal (Rimfrost Genu-
ine™, Olympic Seafood AS, Fosnavåg, Norway), 3) 10 cap-
sules of fish oil supplement (Bioteekin Kalaöljykapseli,
Suomen Bioteekki Oy, Raisio, Finland). The 12.3 g dose of
krill meal was mixed with 150 g of yoghurt (Valiojogurtti®
Sileä vadelma HYLA®, Valio Oy, Oulu, Finland) before
serving. Breakfast was consumed under supervision of the
study nutritionist. The mean duration of breakfast con-
sumption was 15 ± 5 min, when krill oil supplement was
consumed, 15 ± 8 min, when krill meal was consumed and
13 ± 3 min when fish oil supplement was consumed.
The test products were stored in dark, at 4–8°C at the
study center. The portion size of both test products and
active reference each provided about 1 700 mg of
omega-3 polyunsaturated fatty acids (Table 2). The fatty
acid profiling of the krill products and fish oil supple-
ment was done by Nofima BioLab (Fyllingsdalen,
Norway). The fish oil supplement used in this study was
in triglyceride form and was made from sardines and
mackerels.
Standardized lunch, snack, dinner and supper during the
test days
Subjects were served ad libitum standardized lunch, din-
ner and supper during the first day after blood sampling at
4, 8 and 12 hours after start of breakfast ingestion, re-
spectively. For each study subject the similar pre-weighed
portions of foods were served and any leftovers were
weighed with a digital scale (Kern PCB, Kern&SohnTable 2 omega-3 polyunsaturated fatty acid, EPA and DHA co
Test product Dose Total fat Total om
Krill oil 16 capsules 8000 mg 1704 mg
Krill meal 12.3 g 5535 mg 1710 mg
Fish oil 10 capsules 5000 mg 1730 mgGmbH, Balingen-Frommern, Germany). The amounts of
foods consumed at each meal were replicated and pro-
vided for the subjects at day two and three. The same
snack was served after blood sampling at 6 hours after the
start of the breakfast ingestion at each test day.
The lunch meal consisted of commercial vegetable
soup, rye and oat bread, fat spread, cheese, cucumber
and tomato slices. The snack consisted of one pear (or
orange, if the subject was allergic to pear) and 200 ml of
coffee and optional milk and sugar. Dinner consisted of
commercial chicken pasta casserole, rye and oat bread,
fat spread, cheese, cucumber and tomato slices. Supper
consisted of rye and oat bread, fat spread, cheese, ham,
cucumber and tomato slices.
Liquid intake
Only tap water and 200 ml coffee were provided to the
subjects during the first 24 hours of the test. Participants
consumed standardized amounts of tap water with
breakfast (400 ml) and supper (250 ml). In addition, par-
ticipants were asked to consume amounts of tap water
identical to the first day in the two subsequent days.
Background diet, concomitant treatment and medication
At the beginning of the run-in period, participants were
advised to maintain their lifestyles (physical activity, alco-
hol and dietary supplement consumption) and dietary
habits (especially consumption of vegetable oils) through-
out the study. However, consumption of fatty fish (e.g. sal-
mon, herring, sardines, mackerel, vendace, anchovy) and/
or omega-3 fatty acid supplements was forbidden during
all study periods. The subjects were instructed to avoid
vigorous physical activity, alcohol consumption, unusual
foods and heavy meals during 24 hour prior to each test.
Laboratory methods
Blood samples were centrifuged at 2000 × g for 10 mi-
nutes at 10°C after collection. Plasma was immediately
frozen at -70°C for fatty acid analysis. The samples were
shipped frozen under dry ice to the laboratory (Omega-
metrix GmbH, Martinsried, Germany) after completion
of the study.
Lipids were extracted and triglycerides and phospho-
lipids were purified by use of Sep−Pak C-18 mini car-
tridges (Waters, Eschborn, Germany). Fatty acid methyl
esters were formed by acid hydrolysis, and were analyzed
by capillary gas–liquid chromatography on a GS2010ntent of the study products
ega-3 PUFA EPA DHA EPA + DHA
896 mg 504 mg 1 400 mg
692 mg 410 mg 1 102 mg
875 mg 580 mg 1 455 mg
Table 3 Baseline lifestyle characteristics of the
participants (n=15)
Subjects




Other food supplement yes 6 (40%)
no 9 (60%)
Alcohol consumption daily 0 (0%)
weekly 7 (47%)
monthly 5 (33%)
rarely/ not at all 3 (20%)
Commuting (time spent walking
or cycling)
out of work or working
at home
14 (93%)
go by motor vehicle 0 (0%)
<15 min a day 0 (0%)
15–30 min a day 0 (0%)
30–60 min a day 1 (7%)
>60 min a day 0 (0%)
Exercise Daily 2 (13%)
4-6 times a week 6 (40%)
3 times a week 2 (13%)
2 times a week 2 (13%)
once a week 1 (7%)
2-3 times a month 1 (7%)
do not exercise 1 (7%)
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equipped with a SP2560, 100-m column (Supelco,
Bellefonte, Pennsylvania, USA) using hydrogen as car-
rier gas. Fatty acids were identified by comparison
with a standard mixture of fatty acids. The results are
given as percentage of total identified fatty acids.
Blood samples for hematology and clinical chemistry
were taken at the screening visit and at the end of each
test (at 72–74 h after start of breakfast ingestion) after a
10–12 h overnight fast. Blood count, serum creatinine
and gamma-glutamyl transferase concentrations were
assessed and analyzed at United Medix Laboratories Ltd
(Espoo, Finland) with standardized methods. At the
screening visit, serum thyroid-stimulating hormone level
was also analyzed to ensure the health status of the
participants.
Statistical analysis
The planned sample size was based on the primary end-
point, the proportion of EPA +DHA in plasma phospho-
lipid fatty acids during 72 hour follow-up after ingestion,
measured as incremental area under the curve (iAUCPL).
The standard deviation of the iAUC of phospholipid
EPA +DHA proportion was assumed to be 34.7% × h
[8]. A sample size of 15 subjects was planned in order to
be able to detect a difference of 25% × h in mean iAUC
of phospholipid EPA +DHA proportion with a probabil-
ity of 80% at α level of 0.05.
The intention to treat (ITT) population was defined as
all randomized subjects who received at least one dose
of study product.
Incremental areas under the curves of EPA +DHA in
plasma phospholipids and plasma triglycerides were
calculated for each person during each intervention
period according to the trapezoidal rule using the RStu-
dio (Version 0.98.1028–© 2009–2013 RStudio, Inc.),
ignoring the area beneath the fasting percentage.
Maximum increase from baseline (0 min) in percentage
of EPA, DHA and EPA +DHA in plasma triglycerides and
phospholipids were calculated for each person during each
intervention period by deducting the individual baseline
(0 min) proportion from the individual observed peak pro-
portion (cmax) during the 72-h follow-up after adminis-
tration of the study product.
The times (tmax) from baseline to maxima of EPA,
DHA and EPA + DHA in plasma triglycerides and phos-
pholipids were identified for each subject at each inter-
vention period.
Results are presented as means and standard deviations.
Statistical differences were calculated using paired t test for
the comparison of baseline levels and calculations men-
tioned above. Differences with p values < 0.05 were consid-
ered statistically significant. Because of multiple testing,
Bonferroni adjustments were used and p values < 0.017were considered statistically significant for comparison of
the results after intervention with the three different study
products. Data were examined by IBM SPSS Statistics for
windows (release 18.0 Chicago, IL, USA).
Results
Screening
A total of 19 subjects signed informed consent, and was
screened; 17 subjects were randomized. Characteristics
of participants are presented in Table 3. Altogether two
subjects dropped out of the study during the run-in
period. One due to a personal reason and the other par-
ticipant for medical reasons (was prescribed ear surgery).
A total of 15 participants started the first intervention
and all 15 completed the study (Figure 1).
Baseline characteristics
In the ITT population, 7 of 15 subjects were male, the
mean age was 58 ± 11 years, and the mean BMI was
24.9 ± 2.4 kg/m². All participants were Caucasian. Most
of the subjects (12 participants) reported to have some
chronic condition at the beginning of the study (7 par-
ticipants with musculoskeletal and connective tissue dis-
order, 3 with cardiovascular disease, 2 with asthma, 4
Figure 1 Study flow diagram.
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bladder disease). Clinical and biochemical parameters of
the 15 study subjects at baseline and at end of study are
shown in Table 4.
Primary endpoint
The largest EPA +DHA incremental area under 72 h re-
sponse curve in plasma phospholipids (iAUCPL) was de-
tected after krill oil ingestion (mean 89.08 ± 33.36% × h).
The iAUCPL after krill oil ingestion was significantly lar-
ger than after ingestion of krill meal (mean 44.97 ±
18.07% × h, p < 0.001) or fish oil supplement (mean
59.15 ± 22.22% × h, p=0.003). Compared to krill meal,
fish oil supplement showed no significantly larger
iAUCPL (p=0.036). Interestingly, if corrected for the dose
given, the latter two iAUCPL were identical.
As shown in Figure 2, there was a high variability in
response for all study products in the 15 treated sub-
jects. The minimum iAUCPL detected after ingestion of
krill oil was 3.45% × h, after fish oil 6.68% × h and afterkrill meal 4.09% × h. The maximum iAUCPL detected
after ingestion of krill oil was 144.92% × h, after fish oil
94.98% × h and after krill meal 76.57% × h. The max-
imum iAUCPL levels after ingestion of the three different
study products were all detected in subject number 14.
Secondary endpoints
iAUCTG in plasma triglycerides
Compared to the findings in plasma phospholipids, the
mean EPA + DHA incremental area under 72 h response
curve in plasma triglycerides (iAUCTG) showed lower
values. Numerically, the largest iAUCTG in plasma tri-
glycerides was detected after fish oil supplement inges-
tion (mean 35.02 ± 26.54% × h), but the iAUCTG after
ingestion of krill oil (mean 24.46 ± 17.60% × h, p=0.165)
or krill meal (mean 25.05 ± 21.18% × h, p=0.931) were
not significantly smaller. As shown in Figure. 3, the
EPA +DHA levels in plasma triglycerides demonstrated
a high variability in response between the 15 study sub-
jects. The minimum iAUCTG detected after ingestion of
Table 4 Clinical and biochemical parameters at baseline





Mean ± SD Mean ± SD P
Age (years) 57.9 ± 11.1
Gender (male/female) (8/7)
Body weight (kg) 72.0 ± 10.9 71.7 ± 10.9 0.12
BMI 24.9 ± 2.4 24.8 ± 2.4 0.11
leukocytes (109/l) 5.93 ± 1.63 5.63 ± 1.62 0.306
hemoglobin (g/l) 143.5 ± 9.9 140.2 ± 10.2 0.066
hematocrit (%) 43.9 ± 2.7 42.8 ± 3.0 0.066
erythrocytes (1012/l) 4.83 ± 0.37 4.66 ± 0.46 0.014
creatinine (μmol/l) 69.1 ± 10.9 69.7 ± 8.7 0.681
gamma-glutamyl transferase (U/l) 17.0 ± 5.6 14.8 ± 5.8 0.017
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krill meal 0.05% × h. The maximum iAUCTG detected
after ingestion of krill oil was 51.49% × h, after fish oil
97.74% × h and after krill meal 80.63% × h.
EPA levels in plasma phospholipids
The baseline levels for the mean percentage of EPA in
plasma phospholipids showed no significant difference
for the 15 subjects before each intervention.
Numerically, the largest mean maximum increase of
EPA compared to the baseline percentage of total fatty
acids in plasma phospholipids (EPAcmax) was detected
after ingestion of krill oil (1.89 ± 0.38%), but this was not
significantly higher than after fish oil (mean 1.07 ± 0.29%,Figure 2 Incremental area under 72 h response curve of EPA and DH
products (krill oil, fish oil and krill meal) in 15 study subjects.p=0.044) or krill meal (mean 1.20 ± 0.20, p=0.628), which
also held true for the comparison of fish oil and krill meal
(p=0.017). The lowest EPAcmax for all three different study
products were detected in subject number 10.
The time to maximum proportion of EPA in plasma
phospholipids (EPAtmax) showed significant differences
between the three meals. After ingestion of krill meal,
the mean EPAtmax was 13.33 ± 9.88 h. This was signifi-
cantly shorter than compared to krill oil (mean 15.73 ±
15.60 h, p < 0.001) and to fish oil supplement (mean
24.53 ± 20.22, p=0.012). The EPAtmax after ingestion of
krill oil was significantly shorter than after ingestion of
fish oil supplement (p < 0.001).
DHA levels in plasma phospholipids
The baseline levels for the mean percentage of DHA in
plasma phospholipids showed no significant difference
for the 15 subjects before each intervention.
The maximum increase of DHA compared to the base-
line percentage of total fatty acids in plasma phospholipids
(DHAcmax) was detected after ingestion of krill oil (mean
0.53 ± 0.22). This was significantly higher compared to
krill meal (mean 0.26 ± 0.21, p=0.011) but not to fish oil
supplement (mean 0.50 ± 0.27, p=0.769). After ingestion
of fish oil supplement DHAcmax was significantly higher
than after ingestion of krill meal (p=0.011). Compared to
EPAcmax, DHAcmax showed lower levels for each study
meal (3.6 fold lower after krill oil, 2.1 fold lower after fish
oil supplement and 4.6 fold lower after krill meal).
After ingestion of the three different study products the
time to maximum proportion of DHA in plasma phospho-
lipids (DHAtmax) showed no significant difference for theA in plasma phospholipids after ingestion of different study
Figure 3 Incremental area under 72 h response curve of EPA and DHA in plasma triglycerides after ingestion of different study
products (krill oil, fish oil and krill meal) in 15 study subjects.
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maximum proportion of EPA in plasma phospholipids
(EPAtmax), DHAtmax was 3.1 fold higher for krill oil, 2.2
fold higher for fish oil supplement and 2.9 fold higher for
krill meal.
EPA + DHA levels in plasma phospholipids
Analysis of the EPA +DHA levels in plasma phospho-
lipids at baseline showed no significant differences be-
fore intervention with the three study products.
The maximum increase of EPA +DHA compared to
the baseline percentage of total fatty acids in plasma
phospholipids (EPA +DHAcmax) was detected after in-
gestion of krill oil (mean 1.89 ± 0.59%). This was signifi-
cantly higher than after ingestion of fish oil supplement
(mean 1.36 ± 0.47%, p=0.009) and after ingestion of krill
meal (mean 1.12 ± 0.28%, p < 0.001). EPA + DHAcmax
was not different between fish oil supplement and krill
meal groups (p=0.083).
Time to maximum proportion of EPA +DHA in
plasma phospholipids (EPA +DHAtmax) showed no sig-
nificant difference after ingestion of the three different
study products.
EPA, DHA and EPA + DHA levels in plasma triglycerides
As shown in Table 5, EPA, DHA and EPA +DHA levels
at baseline in plasma triglycerides showed no significant
difference between the three study meals.
Also, the maximum increase of EPA, DHA and EPA +
DHA compared to baseline percentage of total fatty
acids, and the time to maximum proportion of EPA,
DHA and EPA +DHA in plasma triglyceride showed nosignificant differences between the three intervention
groups in plasma triglycerides.
A summary of fatty acid results in plasma phospho-
lipids and triglycerides is shown in Table 5.
Adverse events
All adverse events reported by the participants were
non-serious and non-severe. During the run-in period,
only one subject had adverse events. At the interven-
tion periods a total of nine adverse events were reported
(1 after single administration of fish oil supplement, 5 after
single administration of the krill meal and 3 after single
administration of the fish oil supplement). Most of the ad-
verse events were classified as mild. One subject reported
decreased defecation frequency after ingestion of krill oil
and krill meal and the symptom was classified as possibly
related to the study product. Loose stools and heartburn-
ing were both reported by one participant after krill meal
ingestion. Loose stools were classified as possible and
heartburning as probable related to the study product.
One subject reported prolonged bleeding time after blood
sampling at the day when he ingested fish oil supplement.
This symptom was classified as probably related to the
study product.
Clinical and biochemical parameters
Clinical and biochemical parameters at beginning and
at end of study are shown in Table 4. As shown in
Table 4, the mean number of erythrocytes in blood de-
creased statistically significantly from 4.83 (0.37) to 4.66
(0.46) (p=0.014). The changes are considered to be related
to the frequent blood sampling and not to the study
Table 5 Results of fatty acid measurement in plasma phospholipids and triglycerides after intervention with different
study products
A krill oil B fish oil C krill meal A:B C:B A:C
(n=15) (n=15) (n=15)
Mean ± SD Mean ± SD Mean ± SD p p p
iAUC in PL (% x h) 89.08 ± 33.36 59.15 ± 22.22 44.97 ± 18.07 0.003 0.036 <0.001
iAUC in TG (% x h) 24.46 ± 17.60 35.02 ± 26.54 25.04 ± 21.18 0.165 0.035 0.931
EPA in PL at t0 (%) 1.29 ± 0.33 1.31 ± 0.36 1.32 ± 0.41 0.769 0.909 0.769
EPA cmax in PL (%) 1.89 ± 0.38 1.07 ± 0.29 1.20 ± 0.20 0.044 0.017 0.628
EPA tmax in PL (h) 15.73 ± 15.60 24.53 ± 20.22 13.33 ± 9.88 <0.001 0.012 <0.001
EPA max in PL (%) 3.17 ± 0.44 2.38 ± 0.42 2.52 ± 0.43 <0.001 0.108 <0.001
DHA in PL at t0 (%) 4.10 ± 0.81 3.98 ± 0.73 4.35 ± 0.90 0.249 0.023 0.172
DHA cmax in PL (%) 0.53 ± 0.22 0.50 ± 0.27 0.26 ± 0.21 0.796 0.011 0.011
DHA tmax in PL (h) 48.13 ± 23.72 54.53 ± 22.73 38.94 ± 26.12 0.041 0.796 0.090
DHA max in PL (%) 4.63 ± 0.73 4.48 ± 0.80 4.61 ± 0.84 0.090 0.230 0.866
EPA + DHA in PL at t0 (%) 5.39 ± 1.02 5.28 ± 0.91 5.67 ± 1.22 0.424 0.116 0.234
EPA + DHA cmax in PL (%) 1.89 ± 0.59 1.36 ± 0.47 1.12 ± 0.28 0.009 0.083 <0.001
EPA + DHA tmax in PL (h) 21.60 ± 17.92 19.09 ± 35.73 23.87 ± 19.07 0.021 0.044 0.718
EPA + DHA max in PL (%) 7.28 ± 0.88 6.65 ± 1.00 6.78 ± 1.16 <0.001 0.359 0.022
EPA in TG at t0 (%) 0.23 ± 0.12 0.22 ± 0.12 0.24 ± 0.17 0.851 0.650 0.728
EPA cmax in TG (%) 0.65 ± 0.30 0.64 ± 0.44 0.47 ± 0.24 0.919 0.081 0.030
EPA tmax in TG (h) 9.87 ± 17.26 11.20 ± 12.18 8.67 ± 6.44 0.820 0.372 0.742
EPA max in TG (%) 0.88 ± 0.32 0.87 ± 0.50 0.71 ± 0.33 0.876 0.068 0.039
DHA in TG at t0 (%) 0.80 ± 0.33 0.72 ± 0.53 0.75 ± 0.40 0.451 0.749 0.501
DHA cmax in TG (%) 0.54 ± 0.31 0.64 ± 0.52 0.50 ± 0.31 0.477 0.153 0.696
DHA tmax in TG (h) 18.00 ± 24.96 22.53 ± 21.59 18.40 ± 21.14 0.557 0.604 0.966
DHA max in TG (%) 1.34 ± 0.49 1.36 ± 0.75 1.25 ± 0.46 0.836 0.299 0.351
EPA + DHA in TG at t0 (%) 1.03 ± 0.42 0.95 ± 0.58 0.99 ± 0.50 0.446 0.679 0.674
EPA + DHA cmax in TG (%) 1.16 ± 0.55 1.18 ± 0.77 0.92 ± 0.44 0.882 0.104 0.151
EPA + DHA tmax in TG (h) 9.33 ± 17.45 19.73 ± 20.76 16.67 ± 19.65 0.020 0.637 0.281
EPA + DHA max in TG (%) 2.18 ± 0.74 2.13 ± 1.03 1.91 ± 0.73 0.777 0.127 0.092
After Bonferroni adjustment p values <0.017 were considered as statistically significant.
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ber of erythrocytes in blood was within reference range of
the test in all participants and therefore the changes in the
hematological tests are not considered as clinically
significant.
The mean serum gamma-glutamyl transferase activity
decreased from 17.0 (5.6) U/l to 14.8 (5.8) U/l (p=0.017),
and might be due to chance. Serum creatinine concen-
tration remained stable during the study.
Discussion
This randomized open-label trial was conducted to com-
pare the bioavailability of single doses of 1400 mg EPA
plus DHA in a krill oil to 1102 mg EPA plus DHA in
krill meal to 1455 mg EPA plus DHA in a fish oil in
healthy volunteers in a 72 h timeframe. Profiles of EPAand DHA were measured in fatty acids of plasma phos-
pholipids and triglycerides. We found a larger incremen-
tal area under the curve for EPA and DHA in plasma
phospholipid fatty acids (primary endpoint) after krill
oil, as compared to the other two sources of EPA and
DHA.
By and large, plasma phospholipid fatty acid compos-
ition reflects dietary intake from hours to weeks,
whereas triglyceride fatty acid composition reflects diet-
ary intake from hours to days [5,9-12]. The evening be-
fore and during the first 24-hour period of each
consumption of test products, participants consumed
standardized meals. In addition, participants were
instructed not to consume any other sources of EPA and
DHA, and not to change the consumption of vegetable
oil during the study. We conclude that acute changes
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able to the single administration of test products, rather
than any other dietary changes.
The iAUCPL after krill oil had a mean of 89.08 ±
33.36% × h, significantly larger than after ingestion of
krill meal (mean 44.97 ± 18.07% × h, p < 0.001) or fish
oil (mean 59.15 ± 22.22% × h, p=0.003). Our results are
similar to a previous 4 week study, comparing identical
doses of EPA plus DHA (600 mg) in krill oil vs. fish oil
[13]. However, in one previous single dose study, differ-
ences failed to achieve significance [8]. Other studies of
krill oil in humans did not compare identical doses, and
are therefore difficult to compare [14,15]. One explan-
ation for the better bioavailability of EPA and DHA in
krill oil was that some krill oils contain substantial con-
centrations of EPA and DHA as free fatty acids, found in
some, but not all, studies to have a better bioavailability
than EPA and DHA in phospholipids [8,13-15]. The
content of free fatty acids in krill oils varies, depending
on a number of factors [16]. The content of free fatty
acids in the krill oil used in this study, however, was low
(2.6% of EPA and DHA as free fatty acids), supporting
the view that the phospholipids, and not the free fatty
acids, in krill oil are responsible for the higher bioavail-
ability we found.
This view, however, is now challenged by our finding
that the iAUCPL after krill meal was non-significantly
smaller than after fish oil, but was identical, if corrected
for the dose given. While this finding was not reflected
in the iAUCTG, it argues against the interpretation that
the differences in bioavailability we found are due to dif-
ferences in the chemical form of phospholipids vs. tri-
glycerides, as the fat in krill oil and krill meal is
identical. Rather, differences in the food matrix seem to
be responsible. However, based on our data, we cannot
provide a mechanistic explanation, why EPA + DHA had
a better bioavailability in krill oil than in fish oil.
The response to study products varied largely from par-
ticipant to participant (Figures 2 and 3). Before consump-
tion of the study meals and capsules in the morning,
participants were provided a standardized evening meal,
followed by an overnight fast. This was done to minimize
the large effects of concomitant food or fat intake ob-
served in other studies [1,6]. Therefore, we suggest that
the high interindividual variability in response in plasma
phospholipids (iAUCPL krill oil 3.45-144.92% × h; fish oil
6.68-94.98% × h; krill meal 4.09-76.57% × h) and plasma
triglycerides (iAUCTG krill oil was 0.56-51.49% × h, fish oil
2.24-97.74%, krill meal 0.05-80.63% × h) is not explained
by the concomitant food intake or daytime of ingestion.
All maximum iAUCPL-levels were detected in the same
study subject, and in individuals 3, 12, and 13, krill oil did
not display a higher bioavailability than fish oil. Taken to-
gether, our findings confirm the large inter-individualdifferences in uptake of EPA and DHA we and others ob-
served earlier [5,17,18]. These differences remain to be ex-
plained mechanistically.
The variability of our findings on incorporation parame-
ters into plasma phospholipid fatty acids, like maximum
increase from baseline or time to maximum proportion of
EPA, DHA or both combined, probably reflects the high
inter-individual variability just discussed.
Overall, we found smaller AUC’s in response to all three
forms of EPA +DHA in triglyceride fatty acids than in
phospholipid fatty acids, and there was no significant
difference among them. Generally, triglyceride fatty acids
contained smaller percentages of EPA and DHA than
phospholipid fatty acids [19]. The incorporation kinetics
of our study support the interpretation that a smaller pro-
portion of EPA and DHA is being incorporated into trigly-
ceride fatty acids as one mechanism. Other mechanisms,
like increased clearance, might also contribute. Clearly,
however, incorporation into plasma phospholipid or tri-
glyceride fatty acids does not appear to be a random
phenomenon, but rather a regulated process.
Consistently, tmax of EPA in plasma phospholipids or
plasma triglycerides occurred faster than tmax of DHA
after all three preparations studied. However, both tmax
of EPA and tmax of DHA had a shorter timeframe in
plasma triglycerides than in plasma phospholipids. This
argues against a simple crossing of large amounts of
phospholipid or triglycerides molecule across the gastro-
intestinal border, and for a differential handling of EPA
and DHA during absorption among the preparations.
The single administration of krill oil and krill meal
was well tolerated. Few subjects reported mild gastro-
intestinal symptoms after krill product ingestion. Clinical
laboratory evaluation did not show any clinically signifi-
cant changes in laboratory measurements.Strengths and limitations
A strength of our study is that the omega-3 preparations
studied not only contained comparable doses of EPA
and DHA in total but also of each fatty acid individually,
which has not been done in all bioavailability studies of
krill oil [4,5,7,8,13-15] Moreover, we used a cross-over
design in order to limit the effects of the large inter-
individual variability of fatty acid uptake [1]. Limitations
of our study also exist: Although the capsules we used
disintegrated in the stomach, we did not use identical
numbers of identical capsules, as has been suggested re-
cently for krill oil bioavailability studies [14]. However,
although it cannot be excluded, it is difficult to envision
a large impact of 16 vs 10 capsules or of 8 vs. 5 g fat
ingested on the objective parameters we measured.
Clearly, however, our results need to be substantiated in
a longer-term trial using a longer-term parameter of
Köhler et al. Lipids in Health and Disease  (2015) 14:19 Page 10 of 10omega-3 fatty acid bioavailability, like erythrocyte EPA
and DHA, i.e. the Omega-3 Index [1].
Conclusion
In a randomized, single-dose, single-blind, cross-over,
active-reference trial in 15 healthy subjects, we compared
the 72-hour bioavailability of approx. 1 700 mg EPA plus
DHA in krill oil to krill meal and fish oil. Primary end-
point was the incremental area under the curve in plasma
phospholipid fatty acids, reflecting recent dietary intake.
According to the primary endpoint, EPA plus DHA had a
higher bioavailability in krill oil, as compared to krill meal
and fish oil. This was less well reflected in the secondary
endpoints measured. Bioavailability of EPA plus DHA was
not different between krill meal and fish oil, which argues
against the interpretation that phospholipids are better
absorbed than triglycerides. Our findings need to be sub-
stantiated in a longer-term trial using a parameter reflect-
ing tissue EPA plus DHA.
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